Product Images Cyclobenzaprine Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Cyclobenzaprine Hydrochloride NDC 51655-973 by Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 51655 973 87 Master Bottle Label Approval Rev A 05 22
NDC 51655-973-87 Cyclobenzaprine Hydrochloride Tablets USP 10mg, 6 tablets. It's a prescription medicine and the dosage should be taken as per the package insert. The tablets should be stored at a controlled room temperature and kept away from the reach of children. This particular product has been repackaged by Northwind Pharmaceuticals. The GTIN is 0351655973875 and the serial number is 000000000000000. The product expiration date is 00/00/0000 and LOT number is 0000000000.*
Image - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01
IMAGE - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02
This is a list of side effects and their corresponding percentages of cyclobenzaprine HCI tablets at two dosage strengths and a placebo. The side effects include drowsiness, dry mouth, fatigue, headache, and are presented in percentage of occurrence.*
IMAGE - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03
Cyclobenzaprine HCl Tablets, 10 mg have undergone clinical studies which have found that they can cause drowsiness in 39% of individuals using them, dry mouth in 2%, and dizziness in 1%. Additionally, a surveillance program has found that 16% of individuals using these tablets may experience drowsiness, 7% may experience dry mouth, and 3% may experience dizziness.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
